Notes
Metabolic Deesterification of Tazarotene in Human Blood and Rat and HumanLiver Microsomes

https://doi.org/10.1021/js9700558Get rights and content

Abstract

Tazarotene is a novel acetylenic retinoid for the treatment of psoriasis and acne. We examined (1) the hydrolysis of tazarotene in blood from Japanese-American and Caucasian subjects, (2) the esterases responsible for this hydrolysis in human blood, and (3) tazarotene hydrolysis in rat and human liver microsomes. Tazarotene hydrolysis and enzyme inhibition were assessed by monitoring the disappearance of tazarotene and the appearance of its primary metabolite tazarotenic acid by HPLC. In blood, tazarotene was converted mainly to tazarotenic acid via first-order kinetics, and there was no statistically significant difference in the hydrolytic (metabolic) rate of tazarotene in uninhibited Japanese-American and Caucasian blood. Physostigmine (a cholinesterase inhibitor), bis(p-nitrophenyl) phosphate (a carboxylesterase inhibitor), and EDTA (an aromatic esterase inhibitor) did not significantly affect tazarotene hydrolysis in blood. Paraoxon, an inhibitor of all serine esterases including cholinesterase and carboxylesterase, decreased the hydrolysis of tazarotene to tazarotenic acid by 95% in both blood and liver microsomes. In conclusion, blood and liver esterases play a significant role in the hydrolysis of tazarotene to tazarotenic acid, and paraoxon-inhibitable forms of esterases are involved in this hydrolysis in humans.

References and Notes (12)

There are more references available in the full text version of this article.

Cited by (28)

  • Application of PBPK modeling in predicting maternal and fetal pharmacokinetics of levetiracetam during pregnancy

    2023, European Journal of Pharmaceutical Sciences
    Citation Excerpt :

    The method used here was designed to estimate the activity of Type B esterase enzymes in pregnant women via cholinesterase activity in RBCs, because the Type B esterase enzymes involved in the reaction were similar to isoenzymes of cholinesterase. Based on previous data (Strolin Benedetti et al., 2003; Madhu et al., 1997; Patsalos et al., 2006; de Peyster et al., 1994), assuming constant clearance of Type B esterase enzymes in the first and second trimesters, the third-trimester fold was estimated to be 1.2. Further details were provided in the Supplemental section S1.2.

  • Insights into the degradation chemistry of tazarotene, a third generation acetylenic retinoid: LC-HRMS (Orbitrap), LC-MS<sup>n</sup> and NMR characterization of its degradation products, and prediction of their physicochemical and ADMET properties

    2020, Journal of Pharmaceutical and Biomedical Analysis
    Citation Excerpt :

    Chemically, it is ethyl 6-[(4,4­dimethylthiochroman-6-yl)ethynyl]nicotinate [4]. The drug is a monoethyl ester prodrug, which gets hydrolysed by esterases to its active metabolite, tazarotenic acid (6-((4,4-dimethylthiochroman-6-yl)ethynyl)nicotinic acid) [5,6]. Both TZR and its active metabolite (tazarotenic acid) undergo further metabolism via oxidation to corresponding sulfoxides and sulfones [5,7–9].

  • Simultaneous determination of tazarotene and its active metabolite tazarotenic acid in minipig plasma by LC-MS/MS and its application in pharmacokinetic study after topical administration of tazarotene gel

    2015, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
    Citation Excerpt :

    In the therapy of acne vulgaris, tazarotene has shown the property to modulate the pathogenic factors of acne and decrease the proliferation of Propionibacterium acnes [4]. After topical administration, tazarotene undergoes esterase hydrolysis to form its active metabolite tazarotenic acid in skin and plasma, and both analytes are present at low concentration level of pg/mL in human plasma [3,5–7]. The main adverse effects after administration of tazarotene are cutaneous symptoms, asthenia, serum lipid elevation, and hair loss due to high systemic exposure of tazarotene and tazarotenic acid [8].

  • Disposition and biotransformation of the acetylenic retinoid tazarotene in humans

    2005, Journal of Pharmaceutical Sciences
    Citation Excerpt :

    This finding is consistent with a previous pharmacokinetic study that demonstrated the main circulating agent to be tazarotenic acid, with Tmax ranging 2 to 3 h postdose, following tazarotene oral administration.10 The rapid blood hydrolysis of tazarotene is mediated by one or more paraoxon-inhibitable esterases.11 A proportion of tazarotenic acid, accounting for 19.2 ± 3.2% of the dose, was then further metabolized to tazarotenic acid sulfoxide, an inactive metabolite, that was mainly excreted in the urine.

View all citing articles on Scopus
View full text